Cancer Management and Research

Cancer Management and Research is an open-access oncology journal published by Dove Medical Press, established in 2009 with continuous publication, and a 2025 impact factor of 2.6（Cancer Management and Research）是由（Dove Medical Press）出版的开放获取肿瘤学期刊，2009 年创办，采用连续出版模式，2025 年影响因子为 2.6。

Scope

• It covers cancer research and the optimal use of preventive and integrated treatment interventions关注肿瘤研究以及预防性与综合治疗干预的优化应用。
• Sections include epidemiology and prevention, tumour biology and genetics, and biomarker studies栏目包括流行病学与预防、肿瘤生物学与遗传学以及生物标志物研究。
• Cancer therapeutics, both basic and translational, and clinical therapeutics are covered涵盖基础与转化治疗以及临床治疗两大方向。
• Cancer imaging, immunology, radiation oncology, surgical oncology, palliative care and survivorship round out its sections另设肿瘤影像、免疫、放疗、外科肿瘤、姑息治疗与康复者照护等栏目。
• The journal welcomes all oncology article types except meta-analyses, which it no longer considers除不再受理的荟萃分析外，该刊接受各类肿瘤学文章。

History

• The journal began in 2009, with its first volume published that year该刊 2009 年创刊，当年出版首卷。
• It is published by Dove Medical Press, now part of the Taylor and Francis group它由（Dove Medical Press）出版，现属（Taylor & Francis）集团。
• Articles are added continuously during the year and collected into annual volumes文章在年度内陆续上线，再结集为年度卷。
• It applies the ethics principles of COPE and mandatory reporting guidelines such as CONSORT and PRISMA该刊遵循（COPE）伦理准则，并要求使用（CONSORT）、（PRISMA）等报告规范。

Editors

• The editor-in-chief is Professor Yong Teng现任主编为 Yong Teng 教授。
• He leads the cancer therapeutics clinical research section他负责肿瘤治疗临床研究方向。
• Guest editors and section editors handle eleven thematic sections客座编辑与栏目编辑分管十一个主题栏目。
• Peer review is conducted by external reviewers, and authors must upload completed reporting checklists on submission采用外部专家同行评审，作者投稿时须上传填妥的报告清单。